TrialSignal
Clinical trial intelligence report
A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Aug 04, 2026
Report code
NCT07549698-Aug 04, 2026
NCT ID
NCT07549698
Status
RECRUITING
Phase
PHASE1
Sponsor
CRISPR Therapeutics AG
Executive brief
Investment-Ready Snapshot
A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease is a PHASE1 clinical asset sponsored by CRISPR Therapeutics AG in Warm Autoimmune Hemolytic Anemia (WAIHA), ITP
Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura. SEO and diligence focus: CTX112, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07549698
Indication
Warm Autoimmune Hemolytic Anemia (WAIHA)
Modality
gene therapy
Target
CTX112
Intervention
CTX112
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.